Table 2.

Magnitude of change per T allele after glipizide and metformin administration

	β-coefficient	95% CI	P value
Fasting glucose (mg/dL)	1.61	0.036, 3.18	0.04
Glucose AOC (mg/dL)	160.2	−166.6, 487.1	0.34
Fasting glucagon (pg/mL)	−2.5	−4.97, −0.013	0.049
Fasting glucose V2 (mg/dL)	−1.02	−1.96, −0.06	0.04
Fasting glucose V2–V1 (mg/dL)	−1.61	−3.22, 0.02	0.04
GLP-1 total V1 (pmol/L)	1.52	0.22, 2.81	0.02
GLP-1 active V1 (pmol/L)	0.96	0.35, 1.57	0.002
Time to trough glucose at V1 adjusted for baseline glucose (min)	−7.00	−13.21, −0.79	0.027
(Glu0 to Glu­trough)/time (mg/dL/time)	0.023	0.002, 0.045	0.035
(Glu240 to Glutrough)/time (mg/dL/time)	0.024	0.004, 0.044	0.017
Peak insulin at V1 (mU/L)	0.121	−3.146, 3.387	0.942
Time to peak insulin at V1 (min)	−2.139	−9.998, 5.719	0.593
Glucose trough at V1 (mg/dL)	−0.072	−1.477, 1.334	0.920
Glucose trough adjusted for baseline glucose (mg/dL)	−0.727	−1.984, 0.529	0.256
HOMA-β V1	−3.35	−21.72, 15.01	0.720
HOMA-β V2	−4.34	−19.198, 10.50	0.566
HOMA-IR V1	0.068	−0.16, 0.29	0.563
HOMA-IR V2	−0.42	−0.26, 0.18	0.706
Stumvoll index V2	−0.0014	−0.004, 0.001	0.248

AOC, area over the curve; Glu₀, baseline fasting glucose level; Glu₂₄₀, glucose level at 240 min of OGTT; Glu_trough, trough glucose level; V, visit.